Neoadjuvant and Adjuvant Therapy for Renal Cell Carcinoma

Neoadjuvant and Adjuvant Therapy for Renal Cell Carcinoma

Patients undergoing definitive surgery or ablative techniques for nonmetastatic kidney cancer have varying degrees of risk of recurrent disease post procedure. The ultimate goal of “adjuvant therapy” is to reduce the incidence of recurrent disease, and to cure more patients. We summarize the current...

Full description

Bibliographic Details
Main Authors: Naomi B. Haas, Jeffrey Shevach, Ian D. Davis, Tim Eisen, Marine Gross-Gupil, Anil Kapoor, Viraj A. Master, Christopher W. Ryan, Manuela Schimdinger
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Société Internationale d’Urologie Journal
Subjects:
adjuvant therapy
neoadjuvant therapy
vascular endothelial growth factor receptor
tyrosine kinase inhibitor
immune checkpoint inhibitor
renal celll carcinoma
Online Access:https://siuj.org/index.php/siuj/article/download/222/164

Internet

https://siuj.org/index.php/siuj/article/download/222/164

Similar Items